← All trials
NCT06729606
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2021
- Primary completion
- Aug 22, 2022
- Completion date
- Nov 20, 2022
- First posted
- Dec 11, 2024
- Last posted
- Dec 11, 2024
- Enrollment
- 471
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of UtahOfficial
- Prevention and Early Treatment of Acute Lung Injury (PETAL)Collaborator
- Medical Research CouncilCollaborator
- NeuroRx, Inc.Collaborator
- University of CopenhagenCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Collaborator
- University of New South WalesCollaborator
- Department of Veteran AffairsCollaborator
- Department of Veteran AffairsCollaborator
- University of MinnesotaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.